Lokmal Artemether Lumefantrine Caplet Tablet and Oral Paediatric Suspension

Lokmal

 

COMPOSITION

LOKMAL Caplet (Artemether 80mg + Lumefantrine 480mg Per Caplet)

LOKMAL Tablet (Artemether 20mg +Lumefantrine 120mg Per Tablet)

LOKMAL Oral Paediatric Suspension (Artemether 180mg + Lumefantrine 1080mg in 60ml)

 

PROPERTIES

Artemether is the most active derivative of the Artemisinins. Lumefantrine is a synthetic aryl amino alcohol similar to mefloquine and halo- fantrine.

 

INDICATIONS

LOKMAL is indicated for the treatment of malaria in children and adults, caused by all forms of plasmodium including severe malaria caused by multiple drug resistant strains of P. falciparum.

 

PHARMACEUTICAL PRECAUTIONS AND CONTRA INDICATIONS

LOKMAL is contraindicated in individuals who are hypersensitive to artemether and lumefantrine and in the first trimester of pregnancy, except otherwise prescribed by a physician.

Due to long elimination half life of lumefantrine, it is recommended that breast feeding should not start until at least one week after stopping an artemether /Iumefantrine combination treatment.

 

DRUG INTERACTIONS

Specific negative drug – drug interactions were not seen. Artemether potentiates the antimalarial activity of other antimalarial. Grapefruit is known to enhance the absorption of Artemether.

 

SIDE EFFECTS

With Artemether, virtually no side effect has been reported, laboratory abnormalities such as slight rise in transaminases and a decrease in reticulocyte count are rare and transient. A reasonable period should be taken into account before starting a treatment with lumefantrine combinations. Other common side effects may occur as insomnia, nausea, vomiting, diarrhea, coughing and there may be need for medical attention if persistent.

 

RESISTANCE AND RECRUDESCENCE

Resistance of Plasmodium to Artemether has not been observed. An apparent resistance is sometimes seen but is mainly due to multiple broods of Plasmodia developing at different times in the same patient. In controlled studies, recrudescence does not exceed 10% in case of recrudescence (real or apparent) a new complete treatment for three days is advisable.

 

DOSAGE AND ADMINISTRATION

BODY WEIGHT (AGE) CAPLETS TABLETS
Adult and Children  35 kg 14 Years and above) 1 Caplet taken every 12 hours for 3 days DAY 1 DAY 2 DAY 3
0 Hr 8Hrs Morning Night Morning Night
4 Tablets 4 Tablets 4 Tablets 4 Tablets 4 Tablets 4 Tablets
25-35 kg (9-13 Years)   DAY 1 DAY 2 DAY 3
  0 Hr 8Hrs Morning Night Morning Night
  3 Tablets 3 Tablets 3 Tablets 3 Tablets 3 Tablets 3 Tablets
15-25 kg (4-8 Years)   DAY 1 DAY 2 DAY 3
  0 Hr 8Hrs Morning Night Morning Night
  2 Tablets 2 Tablets 2 Tablets 2 Tablets 2 Tablets 2 Tablets
5-15 kg (1-3 Years)   DAY 1 DAY 2 DAY 3
  0 Hr 8Hrs Morning Night Morning Night
  1 Tablets 1 Tablets 1 Tablets 1 Tablets 1 Tablets 1 Tablets

SUSPENSIONS

  DAY 1 DAY 2 DAY 3 Ensure the second dose is given 8hrs after taking the first dose
5 kg-14 kg (6 months – 3 Years) 0 Hr 8Hrs Morning Night Morning Night
7ml 7ml 7ml 7ml 7ml 7ml
15 kg- 25kg (4-8 Years) 14ml 14ml 14ml 14ml 14ml 14ml

 

DIRECTION FOR RECONSTITUTION

To reconstitute the suspension, add about 40ml of freshly boiled and cooled water to the powder in the bottle, shake well until all the powder has dispersed, then add more water to the mark on the Label.

 

PHARMACEUTICAL PRECAUTIONS

LOKMAL should be stored below 25°C in a closed bottle.

LOKMAL SUSPENSION Powders are stable, once the suspension has been made up, it is stable for a maximum of 14 days. Longer conservation, is not recommended.

 

KEEP ALL MEDICATIONS OUT OF THE REACH OF CHILDREN

 

Shelf Life

2 Years

 

DISPENSING CATEGORY

Over the counter.

 

PRESENTATION

LOKMAL CAPLETS: Blister Pack of Six Caplets.

LOKMAL TABLET: Blister Pack of 6×2, 6×4 Tablets.

LOKMAL ORAL DRY POWDER for reconstitution to 60ml. Each cardboard box contains 1 bottle.

 

Manufactured by

EMZOR PHARMACEUTICAL INDUSTRIES LIMITED

Plot 3C, BLOCK A Aswani Market Road, Isolo-Lagos Nigeria.

customerservice@emzorpharma.com

www.emzorpharma.com

Leave a Reply